Cargando…

Integrated Metabolomics and Network Pharmacology Study on the Mechanism of Kangfuxiaoyan Suppository for Treating Chronic Pelvic Inflammatory Disease

Kangfuxiaoyan suppository (KFXYS) is a commonly used traditional Chinese medicine (TCM) preparation for the treatment of chronic pelvic inflammatory disease (CPID) clinically, and its safety and effectiveness have been well verified. However, the potential mechanism remains unclear. The integrated s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhengyi, Xie, Ziye, Lv, Shujing, Shi, Yulian, Zhai, Chuanjia, Li, Xuejiao, Qiao, Bin, Gao, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854495/
https://www.ncbi.nlm.nih.gov/pubmed/35185568
http://dx.doi.org/10.3389/fphar.2022.812587
_version_ 1784653450793975808
author Zhang, Zhengyi
Xie, Ziye
Lv, Shujing
Shi, Yulian
Zhai, Chuanjia
Li, Xuejiao
Qiao, Bin
Gao, Xiaoyan
author_facet Zhang, Zhengyi
Xie, Ziye
Lv, Shujing
Shi, Yulian
Zhai, Chuanjia
Li, Xuejiao
Qiao, Bin
Gao, Xiaoyan
author_sort Zhang, Zhengyi
collection PubMed
description Kangfuxiaoyan suppository (KFXYS) is a commonly used traditional Chinese medicine (TCM) preparation for the treatment of chronic pelvic inflammatory disease (CPID) clinically, and its safety and effectiveness have been well verified. However, the potential mechanism remains unclear. The integrated strategy of metabolomics and network pharmacology was employed in the study to reveal the potential mechanism of KFXYS in the treatment of CPID. Our research consists of five steps. First, the effect of KFXYS in reversing uterine inflammation indexes was verified. Second, based on the comprehensive characterization of 123 chemical ingredients of KFXYS, the ingredients of KFXYS absorbed into blood were identified by UPLC-Q-TOF/MS, then ADME research was carried out on the main ingredients. Third, the differential metabolites with significant correlation to inflammatory indexes were discovered by metabolomics and correlation analysis. Fourth, the potential targets and pathways of KFXYS in treating CPID were predicted by network pharmacology based on the ingredients which had good ADME behavior. Fifth, the proteins in common pathways of metabolomics and network pharmacology were used to screen the key targets from the potential targets of network pharmacology, and the potential mechanism of KFXYS in treating CPID was clarified. As a result, KFXYS significantly reversed the uterine inflammation indexes, including IL-1 and IL-6. The ingredients absorbed into blood including matrine, sophocarpine, aloin, esculetin-O-glucuronide, 7,4′-dihydroxyisoflavone-O-glucuronide, and 4′-methoxyisoflavone-7-O-glucuronide had good ADME behavior in vivo. Among the differential metabolites, Leukotriene A4, 5-Hydroxyindoleacetic acid, Ornithine, Arginine, and PC (20:1 (11Z)/20:4 (8Z,11Z,14Z,17Z)) were significant correlation to inflammation indexes. The integration analysis of metabolomics and network pharmacology shows that KFXYS may regulate the key targets including ARG1, NOS2, NOS3, etc. We speculate that ingredients of KFXYS, such as matrine, sophocarpine, aloin etc. act on the key proteins including ARG1, NOS2, and NOS3, to exert anti-inflammatory effect.
format Online
Article
Text
id pubmed-8854495
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88544952022-02-19 Integrated Metabolomics and Network Pharmacology Study on the Mechanism of Kangfuxiaoyan Suppository for Treating Chronic Pelvic Inflammatory Disease Zhang, Zhengyi Xie, Ziye Lv, Shujing Shi, Yulian Zhai, Chuanjia Li, Xuejiao Qiao, Bin Gao, Xiaoyan Front Pharmacol Pharmacology Kangfuxiaoyan suppository (KFXYS) is a commonly used traditional Chinese medicine (TCM) preparation for the treatment of chronic pelvic inflammatory disease (CPID) clinically, and its safety and effectiveness have been well verified. However, the potential mechanism remains unclear. The integrated strategy of metabolomics and network pharmacology was employed in the study to reveal the potential mechanism of KFXYS in the treatment of CPID. Our research consists of five steps. First, the effect of KFXYS in reversing uterine inflammation indexes was verified. Second, based on the comprehensive characterization of 123 chemical ingredients of KFXYS, the ingredients of KFXYS absorbed into blood were identified by UPLC-Q-TOF/MS, then ADME research was carried out on the main ingredients. Third, the differential metabolites with significant correlation to inflammatory indexes were discovered by metabolomics and correlation analysis. Fourth, the potential targets and pathways of KFXYS in treating CPID were predicted by network pharmacology based on the ingredients which had good ADME behavior. Fifth, the proteins in common pathways of metabolomics and network pharmacology were used to screen the key targets from the potential targets of network pharmacology, and the potential mechanism of KFXYS in treating CPID was clarified. As a result, KFXYS significantly reversed the uterine inflammation indexes, including IL-1 and IL-6. The ingredients absorbed into blood including matrine, sophocarpine, aloin, esculetin-O-glucuronide, 7,4′-dihydroxyisoflavone-O-glucuronide, and 4′-methoxyisoflavone-7-O-glucuronide had good ADME behavior in vivo. Among the differential metabolites, Leukotriene A4, 5-Hydroxyindoleacetic acid, Ornithine, Arginine, and PC (20:1 (11Z)/20:4 (8Z,11Z,14Z,17Z)) were significant correlation to inflammation indexes. The integration analysis of metabolomics and network pharmacology shows that KFXYS may regulate the key targets including ARG1, NOS2, NOS3, etc. We speculate that ingredients of KFXYS, such as matrine, sophocarpine, aloin etc. act on the key proteins including ARG1, NOS2, and NOS3, to exert anti-inflammatory effect. Frontiers Media S.A. 2022-02-04 /pmc/articles/PMC8854495/ /pubmed/35185568 http://dx.doi.org/10.3389/fphar.2022.812587 Text en Copyright © 2022 Zhang, Xie, Lv, Shi, Zhai, Li, Qiao and Gao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Zhengyi
Xie, Ziye
Lv, Shujing
Shi, Yulian
Zhai, Chuanjia
Li, Xuejiao
Qiao, Bin
Gao, Xiaoyan
Integrated Metabolomics and Network Pharmacology Study on the Mechanism of Kangfuxiaoyan Suppository for Treating Chronic Pelvic Inflammatory Disease
title Integrated Metabolomics and Network Pharmacology Study on the Mechanism of Kangfuxiaoyan Suppository for Treating Chronic Pelvic Inflammatory Disease
title_full Integrated Metabolomics and Network Pharmacology Study on the Mechanism of Kangfuxiaoyan Suppository for Treating Chronic Pelvic Inflammatory Disease
title_fullStr Integrated Metabolomics and Network Pharmacology Study on the Mechanism of Kangfuxiaoyan Suppository for Treating Chronic Pelvic Inflammatory Disease
title_full_unstemmed Integrated Metabolomics and Network Pharmacology Study on the Mechanism of Kangfuxiaoyan Suppository for Treating Chronic Pelvic Inflammatory Disease
title_short Integrated Metabolomics and Network Pharmacology Study on the Mechanism of Kangfuxiaoyan Suppository for Treating Chronic Pelvic Inflammatory Disease
title_sort integrated metabolomics and network pharmacology study on the mechanism of kangfuxiaoyan suppository for treating chronic pelvic inflammatory disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854495/
https://www.ncbi.nlm.nih.gov/pubmed/35185568
http://dx.doi.org/10.3389/fphar.2022.812587
work_keys_str_mv AT zhangzhengyi integratedmetabolomicsandnetworkpharmacologystudyonthemechanismofkangfuxiaoyansuppositoryfortreatingchronicpelvicinflammatorydisease
AT xieziye integratedmetabolomicsandnetworkpharmacologystudyonthemechanismofkangfuxiaoyansuppositoryfortreatingchronicpelvicinflammatorydisease
AT lvshujing integratedmetabolomicsandnetworkpharmacologystudyonthemechanismofkangfuxiaoyansuppositoryfortreatingchronicpelvicinflammatorydisease
AT shiyulian integratedmetabolomicsandnetworkpharmacologystudyonthemechanismofkangfuxiaoyansuppositoryfortreatingchronicpelvicinflammatorydisease
AT zhaichuanjia integratedmetabolomicsandnetworkpharmacologystudyonthemechanismofkangfuxiaoyansuppositoryfortreatingchronicpelvicinflammatorydisease
AT lixuejiao integratedmetabolomicsandnetworkpharmacologystudyonthemechanismofkangfuxiaoyansuppositoryfortreatingchronicpelvicinflammatorydisease
AT qiaobin integratedmetabolomicsandnetworkpharmacologystudyonthemechanismofkangfuxiaoyansuppositoryfortreatingchronicpelvicinflammatorydisease
AT gaoxiaoyan integratedmetabolomicsandnetworkpharmacologystudyonthemechanismofkangfuxiaoyansuppositoryfortreatingchronicpelvicinflammatorydisease